Multiphasic Oral Contraceptive Method for Extended Cycle Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Extended monophasic oral contraceptive regimens suffer from poor initial cycle control and excessive breakthrough bleeding, which becomes more frequent and difficult to suppress as treatment duration extends beyond a month, often resulting in irregular bleeding and increased risk of blood clotting side effects from higher estrogen doses.
Innovation Solution
A multiphasic contraceptive method involving sequential administration of Phase I, II, III, and IV compositions with increasing estrogen doses over 54 to 58 days, followed by a Phase IV with reduced or placebo estrogen, to maintain endometrial integrity and reduce breakthrough bleeding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If extended monophasic oral contraceptive regimens are used, then contraceptive coverage is extended beyond one month, but breakthrough bleeding increases and cycle control deteriorates
Solution Approach 1:
The patent applies dynamics by transitioning from a static monophasic regimen to a dynamic multiphasic regimen where estrogen and progestin doses are systematically varied across four phases. Phase I uses low estrogen (10-35 mcg) with high progestin (0.75-1.5 mg), Phase II increases estrogen (20-40 mcg) with moderate progestin (0.5-1.0 mg), Phase III uses high estrogen (30-50 mcg) with low progestin (0.35-0.75 mg), and Phase IV reduces both hormones. This dynamic dosing strategy adapts to the physiological needs of different cycle stages, maintaining endometrial stability and preventing breakthrough bleeding while extending contraceptive coverage to 98 days.
Solution Approach 2:
The patent implements parameter changes by systematically modifying hormone dosage parameters across phases. Estrogen doses progress from 10-35 mcg in Phase I to 20-40 mcg in Phase II, then to 30-50 mcg in Phase III, before reduction in Phase IV. Progestin doses follow a complementary pattern from 0.75-1.5 mg to 0.5-1.0 mg to 0.35-0.75 mg. These controlled parameter changes optimize endometrial response at different treatment stages, preventing the breakthrough bleeding that occurs with extended monophasic regimens while maintaining contraceptive efficacy.
2Object-generated harmful factors
If higher estrogen doses are used to suppress breakthrough bleeding in extended regimens, then bleeding is reduced, but risk of blood clotting side effects increases
Solution Approach 1:
The patent applies periodic action by administering estrogen in a cyclic pattern across four phases rather than continuously at high levels. Phase I uses low estrogen (10-35 mcg) during the initial stabilization period, Phase II increases to moderate levels (20-40 mcg), Phase III reaches peak levels (30-50 mcg) when endometrial stability is most needed, and Phase IV reduces doses. This periodic dosing provides bleeding suppression when necessary while avoiding sustained high-dose exposure that increases thrombotic risk, reducing overall estrogenic burden compared to extended monophasic regimens.
Solution Approach 2:
The patent implements local quality by tailoring hormone doses to specific physiological needs at different cycle phases. Phase I uses low estrogen with high progestin to establish initial endometrial stability, Phase II uses moderate estrogen with moderate progestin for transition, Phase III uses high estrogen with low progestin for maximum bleeding suppression during the extended coverage period, and Phase IV reduces both hormones for withdrawal. This localized optimization of hormone quality and dosage at each phase provides effective bleeding control without requiring uniformly high estrogen doses throughout the extended regimen, thereby minimizing blood clotting risks.
3Productivity
If extended monophasic regimens are administered, then fewer menstrual cycles occur per year, but irregular bleeding becomes more frequent and difficult to suppress
Solution Approach 1:
The patent applies dynamics by implementing a four-phase dosing strategy that actively manages endometrial stability throughout the extended 98-day cycle. Phase I (days 1-14) uses low estrogen (10-35 mcg) with high progestin (0.75-1.5 mg) to establish initial stability, Phase II (days 15-28) increases estrogen to moderate levels (20-40 mcg) with moderate progestin (0.5-1.0 mg) for transition, Phase III (days 29-63) uses high estrogen (30-50 mcg) with low progestin (0.35-0.75 mg) to maintain stability during the extended period, and Phase IV (days 64-98) reduces both hormones for controlled withdrawal. This dynamic adjustment prevents the irregular bleeding that plagues extended monophasic regimens while achieving the productivity goal of fewer menstrual cycles per year.
Solution Approach 2:
The patent implements parameter changes by systematically varying hormone dosages across phases to maintain endometrial stability. Estrogen parameters progress from 10-35 mcg in Phase I to 20-40 mcg in Phase II, then to 30-50 mcg in Phase III, before reduction in Phase IV. Progestin parameters follow a complementary pattern from 0.75-1.5 mg to 0.5-1.0 mg to 0.35-0.75 mg. These controlled parameter changes ensure consistent endometrial response throughout the extended regimen, preventing the irregular bleeding patterns that occur with fixed-dose extended monophasic regimens while achieving reduced menstrual frequency.
Data Source
AI summary
A multiphasic method of contraception comprising the steps of sequentially administering to a female of child bearing age a Phase I composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg norethiiidrpne acetate and an estrogen in an amount equivalent to about 5 to aboμt 15 mcg of ethinyl estradiol for about 7 to about 14 days; a Phase II composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 10 to about 25 meg of ethinyl estradiol for about 14 to about 22 days; a Phase m composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 15 to about 35 meg of ethinyl estradiol for about 20 to about 31 days; and an optional Phase IV composition containing (i) an estrogen in an amount equivalent to about 5 to about 20 meg of ethinyl estradiol, or (ii) a placebo or a non-steroidal component, or (iii) a combination of (i) and (ii), for about 2 to about 8 days. The ethinyl estradiol equivalent amount of estrogen in each of the successive Phases II and III is at least 5 meg greater than the ethinyl estradiol equivalent amount of estrogen in the immediately-preceding phase.